CA2702635A1 - A new biomarker for monitoring development of diseases and assessing the efficacy of therapies - Google Patents
A new biomarker for monitoring development of diseases and assessing the efficacy of therapies Download PDFInfo
- Publication number
- CA2702635A1 CA2702635A1 CA2702635A CA2702635A CA2702635A1 CA 2702635 A1 CA2702635 A1 CA 2702635A1 CA 2702635 A CA2702635 A CA 2702635A CA 2702635 A CA2702635 A CA 2702635A CA 2702635 A1 CA2702635 A1 CA 2702635A1
- Authority
- CA
- Canada
- Prior art keywords
- disease
- sample
- protein
- patient
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 32
- 201000010099 disease Diseases 0.000 title claims abstract description 31
- 239000000090 biomarker Substances 0.000 title claims abstract description 15
- 238000002560 therapeutic procedure Methods 0.000 title claims abstract description 14
- 238000012544 monitoring process Methods 0.000 title claims abstract description 11
- 238000011161 development Methods 0.000 title claims abstract description 9
- 238000000034 method Methods 0.000 claims abstract description 26
- 239000012530 fluid Substances 0.000 claims abstract description 18
- 102000004127 Cytokines Human genes 0.000 claims abstract description 9
- 108090000695 Cytokines Proteins 0.000 claims abstract description 9
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims abstract description 7
- 102100022464 5'-nucleotidase Human genes 0.000 claims abstract 12
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 claims abstract 12
- 230000000694 effects Effects 0.000 claims description 32
- 206010069351 acute lung injury Diseases 0.000 claims description 16
- 206010028980 Neoplasm Diseases 0.000 claims description 14
- 206010063837 Reperfusion injury Diseases 0.000 claims description 13
- 201000011510 cancer Diseases 0.000 claims description 13
- 239000011230 binding agent Substances 0.000 claims description 12
- 230000004968 inflammatory condition Effects 0.000 claims description 11
- 239000000758 substrate Substances 0.000 claims description 11
- 208000014674 injury Diseases 0.000 claims description 10
- 238000003556 assay Methods 0.000 claims description 9
- 230000008733 trauma Effects 0.000 claims description 8
- 210000000056 organ Anatomy 0.000 claims description 7
- 238000004809 thin layer chromatography Methods 0.000 claims description 7
- 238000002054 transplantation Methods 0.000 claims description 7
- 208000034486 Multi-organ failure Diseases 0.000 claims description 6
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 claims description 6
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims description 6
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 claims description 6
- 208000010125 myocardial infarction Diseases 0.000 claims description 6
- 206010027476 Metastases Diseases 0.000 claims description 5
- 230000009401 metastasis Effects 0.000 claims description 5
- 206010061623 Adverse drug reaction Diseases 0.000 claims description 4
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 claims description 4
- 230000008859 change Effects 0.000 claims description 4
- 208000027866 inflammatory disease Diseases 0.000 claims description 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 2
- 206010007759 Cataract nuclear Diseases 0.000 claims description 2
- 206010012289 Dementia Diseases 0.000 claims description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 2
- 208000029552 nuclear cataract Diseases 0.000 claims description 2
- 208000002815 pulmonary hypertension Diseases 0.000 claims description 2
- 241000699670 Mus sp. Species 0.000 description 22
- 102000004169 proteins and genes Human genes 0.000 description 20
- 108090000623 proteins and genes Proteins 0.000 description 20
- 210000001519 tissue Anatomy 0.000 description 18
- 239000000523 sample Substances 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 12
- 210000004072 lung Anatomy 0.000 description 12
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 11
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 10
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 10
- LNQVTSROQXJCDD-UHFFFAOYSA-N adenosine monophosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)C(OP(O)(O)=O)C1O LNQVTSROQXJCDD-UHFFFAOYSA-N 0.000 description 9
- 102000014150 Interferons Human genes 0.000 description 7
- 108010050904 Interferons Proteins 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 230000010410 reperfusion Effects 0.000 description 7
- 206010033645 Pancreatitis Diseases 0.000 description 6
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 5
- 229920002307 Dextran Polymers 0.000 description 5
- 102000003996 Interferon-beta Human genes 0.000 description 5
- 108090000467 Interferon-beta Proteins 0.000 description 5
- 229960005305 adenosine Drugs 0.000 description 5
- 229940079322 interferon Drugs 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 230000002792 vascular Effects 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 4
- 229960001388 interferon-beta Drugs 0.000 description 4
- 208000028867 ischemia Diseases 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000035699 permeability Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 206010027654 Allergic conditions Diseases 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 208000017667 Chronic Disease Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000003511 endothelial effect Effects 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 201000006417 multiple sclerosis Diseases 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000004043 responsiveness Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- GRSZFWQUAKGDAV-KQYNXXCUSA-N IMP Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=O)=C2N=C1 GRSZFWQUAKGDAV-KQYNXXCUSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000006992 Interferon-alpha Human genes 0.000 description 2
- 108010047761 Interferon-alpha Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 206010022680 Intestinal ischaemia Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 206010053159 Organ failure Diseases 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 239000003524 antilipemic agent Substances 0.000 description 2
- 208000037979 autoimmune inflammatory disease Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000009266 disease activity Effects 0.000 description 2
- 238000010191 image analysis Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 229940047124 interferons Drugs 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- 238000002350 laparotomy Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000001363 mesenteric artery superior Anatomy 0.000 description 2
- 238000001000 micrograph Methods 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- 150000003833 nucleoside derivatives Chemical class 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 230000008728 vascular permeability Effects 0.000 description 2
- ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 description 1
- 229940093475 2-ethoxyethanol Drugs 0.000 description 1
- UPXRTVAIJMUAQR-UHFFFAOYSA-N 4-(9h-fluoren-9-ylmethoxycarbonylamino)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound C1C(C(O)=O)N(C(=O)OC(C)(C)C)CC1NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 UPXRTVAIJMUAQR-UHFFFAOYSA-N 0.000 description 1
- 102000004008 5'-Nucleotidase Human genes 0.000 description 1
- MCWDCZIDTUQRHK-FDDDBJFASA-N 6-deoxyinosine 5'-phosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C2=NC=NC=C2N=C1 MCWDCZIDTUQRHK-FDDDBJFASA-N 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 206010061660 Artery dissection Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 238000009020 BCA Protein Assay Kit Methods 0.000 description 1
- 229940127272 CD73 inhibitor Drugs 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 206010053648 Vascular occlusion Diseases 0.000 description 1
- 208000010285 Ventilator-Induced Lung Injury Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- OLCWZBFDIYXLAA-IOSLPCCCSA-N adenosine 5'-methylenediphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)CP(O)(O)=O)[C@@H](O)[C@H]1O OLCWZBFDIYXLAA-IOSLPCCCSA-N 0.000 description 1
- 229950006790 adenosine phosphate Drugs 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 208000008445 altitude sickness Diseases 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 230000002542 deteriorative effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000003028 elevating effect Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000007824 enzymatic assay Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N glycerol 1-phosphate Chemical compound OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 229960004184 ketamine hydrochloride Drugs 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000003975 mesenteric artery Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 108010043671 prostatic acid phosphatase Proteins 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000006453 vascular barrier function Effects 0.000 description 1
- 208000021331 vascular occlusion disease Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
- G01N2800/245—Transplantation related diseases, e.g. graft versus host disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI20070795 | 2007-10-24 | ||
| FI20070795A FI20070795A0 (fi) | 2007-10-24 | 2007-10-24 | Uusi biomarkkeri sairauksien kehittämisen tarkkailuun ja terapioiden tehon arviointiin |
| PCT/FI2008/050576 WO2009053523A1 (en) | 2007-10-24 | 2008-10-15 | A new biomarker for monitoring development of diseases and assessing the efficacy of therapies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2702635A1 true CA2702635A1 (en) | 2009-04-30 |
Family
ID=38656804
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2702635A Abandoned CA2702635A1 (en) | 2007-10-24 | 2008-10-15 | A new biomarker for monitoring development of diseases and assessing the efficacy of therapies |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20100209942A1 (enExample) |
| EP (2) | EP2201376B1 (enExample) |
| JP (2) | JP4982610B2 (enExample) |
| KR (2) | KR20160029869A (enExample) |
| CA (1) | CA2702635A1 (enExample) |
| CY (2) | CY1113403T1 (enExample) |
| DK (2) | DK2201376T3 (enExample) |
| ES (2) | ES2532361T3 (enExample) |
| FI (1) | FI20070795A0 (enExample) |
| HR (2) | HRP20120743T1 (enExample) |
| PL (2) | PL2503338T3 (enExample) |
| PT (2) | PT2503338E (enExample) |
| SI (2) | SI2503338T1 (enExample) |
| WO (1) | WO2009053523A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2878025C (en) | 2008-01-18 | 2018-12-11 | President And Fellows Of Harvard College | Methods of detecting signatures of disease or conditions in bodily fluids |
| CA2806301A1 (en) | 2010-07-23 | 2012-01-26 | President And Fellows Of Harvard College | Methods of detecting cardiovascular diseases or conditions |
| MX2013000917A (es) | 2010-07-23 | 2013-07-05 | Harvard College | Metodos para detectar las enfermedades o condiciones usando celulas fagociticas. |
| WO2012012717A1 (en) | 2010-07-23 | 2012-01-26 | President And Fellows Of Harvard College | Methods of detecting prenatal or pregnancy-related diseases or conditions |
| AU2011280997A1 (en) | 2010-07-23 | 2013-02-28 | President And Fellows Of Harvard College | Methods of detecting autoimmune or immune-related diseases or conditions |
| KR20130041961A (ko) | 2010-07-23 | 2013-04-25 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 체액에서 질환 또는 상태의 특징을 검출하는 방법 |
| KR20150035818A (ko) | 2012-06-15 | 2015-04-07 | 해리 스타일리 | 순환 병든 세포를 사용하여 질환 또는 병태를 검출하는 방법 |
| JP2015522260A (ja) | 2012-06-15 | 2015-08-06 | ハリー スティリ， | 疾患または状態を検出する方法 |
| BR112015018213B1 (pt) * | 2013-02-14 | 2022-12-20 | Faron Pharmaceuticals Oy | Métodos para determinar a síndrome da angústia respiratória aguda (ards) e para monitorar o desenvolvimento desta e kit para diagnóstico |
| WO2014164362A1 (en) | 2013-03-09 | 2014-10-09 | Harry Stylli | Methods of detecting prostate cancer |
| EP2965077B1 (en) | 2013-03-09 | 2022-07-13 | Harry Stylli | Methods of detecting cancer |
| EP4428251A3 (en) | 2014-09-11 | 2024-12-18 | Immunis.AI, Inc. | Methods of detecting prostate cancer |
| DK3221363T3 (da) | 2014-11-21 | 2020-08-10 | Bristol Myers Squibb Co | Antistoffer mod cd73 og anvendelser deraf |
| HRP20201756T8 (hr) | 2014-11-21 | 2021-08-20 | Bristol-Myers Squibb Company | Antitijela koja sadrže modificirane regije teškog lanca |
| GB201706747D0 (en) * | 2017-04-27 | 2017-06-14 | Queen Mary | Method and apparatus for determining the efficacy of statins for treating inflammatory diseases in idividual patients |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0854934A4 (en) * | 1995-08-18 | 2000-09-06 | Donald W Landry | DETECTION OF ORGANIC COMPOUNDS BY REGULATION OF ANTIBODY CATALYZED REACTIONS |
| WO1997013875A1 (en) * | 1995-10-13 | 1997-04-17 | Imperial College Of Science, Technology & Medicine | Methods for predicting the outcome of persistent hbv infection and the outcome of cytokine therapy |
| HUP0002003A3 (en) * | 2000-05-24 | 2003-01-28 | Pronuk Biotechnologia Kft | Process and reagent-kit for determining of 5'-nucleotidase activity |
| WO2002077174A2 (en) * | 2001-03-27 | 2002-10-03 | Zymogenetics, Inc. | Human cytokine receptor |
| WO2004079013A1 (en) * | 2003-03-03 | 2004-09-16 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Ecto-5’-nucleotidase (cd73) used in the diagnosis and the treatment of pancreatic cancer |
| PL1608400T3 (pl) * | 2003-03-28 | 2010-11-30 | Faron Pharmaceuticals Oy | Podwyższanie poziomu adenozyny przez indukowaną przez cytokiny ekspresję CD73 |
| FI20030467A0 (fi) * | 2003-03-28 | 2003-03-28 | Sirpa Jalkanen | Menetelmä tulehdustilojen hoitamiseen |
| EP1664073A2 (en) * | 2003-06-03 | 2006-06-07 | The Regents of the University of California | Compositions and methods for treatment of disease with acetylated disaccharides |
| ATE520979T1 (de) * | 2005-08-24 | 2011-09-15 | Bristol Myers Squibb Co | Biomarker und verfahren zur bestimmung der empfindlichkeit gegenüber modulatoren des egf(epidermal growth factor)-rezeptors |
| FI20051003A0 (fi) | 2005-10-07 | 2005-10-07 | Faron Pharmaceuticals Oy | Menetelmä iskemiareperfuusiovaurion tai monielinhäiriön hoitamiseksi tai estämiseksi |
| WO2007107598A1 (en) * | 2006-03-21 | 2007-09-27 | Heinrich-Heine-Universität Düsseldorf | Phosphorylated a2a receptor agonists |
| EP2041574B1 (en) * | 2006-07-14 | 2016-11-16 | The Regents of The University of California | Cancer biomarkers and methods of use threof |
-
2007
- 2007-10-24 FI FI20070795A patent/FI20070795A0/fi not_active Application Discontinuation
-
2008
- 2008-10-15 WO PCT/FI2008/050576 patent/WO2009053523A1/en not_active Ceased
- 2008-10-15 SI SI200831377T patent/SI2503338T1/sl unknown
- 2008-10-15 KR KR1020167005473A patent/KR20160029869A/ko not_active Ceased
- 2008-10-15 DK DK08842581.4T patent/DK2201376T3/da active
- 2008-10-15 ES ES12002502.8T patent/ES2532361T3/es active Active
- 2008-10-15 SI SI200830723T patent/SI2201376T1/sl unknown
- 2008-10-15 PL PL12002502T patent/PL2503338T3/pl unknown
- 2008-10-15 CA CA2702635A patent/CA2702635A1/en not_active Abandoned
- 2008-10-15 EP EP08842581A patent/EP2201376B1/en active Active
- 2008-10-15 KR KR1020107006430A patent/KR20100059902A/ko not_active Ceased
- 2008-10-15 PT PT12002502T patent/PT2503338E/pt unknown
- 2008-10-15 ES ES08842581T patent/ES2389751T3/es active Active
- 2008-10-15 HR HRP20120743AT patent/HRP20120743T1/hr unknown
- 2008-10-15 US US12/679,785 patent/US20100209942A1/en not_active Abandoned
- 2008-10-15 JP JP2010530497A patent/JP4982610B2/ja not_active Expired - Fee Related
- 2008-10-15 PL PL08842581T patent/PL2201376T3/pl unknown
- 2008-10-15 EP EP12002502.8A patent/EP2503338B1/en active Active
- 2008-10-15 DK DK12002502T patent/DK2503338T3/en active
- 2008-10-15 PT PT08842581T patent/PT2201376E/pt unknown
-
2012
- 2012-04-23 JP JP2012098081A patent/JP5619810B2/ja not_active Expired - Fee Related
- 2012-10-04 CY CY20121100924T patent/CY1113403T1/el unknown
-
2015
- 2015-02-16 HR HRP20150181TT patent/HRP20150181T1/hr unknown
- 2015-03-06 CY CY20151100234T patent/CY1116089T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20160029869A (ko) | 2016-03-15 |
| EP2201376B1 (en) | 2012-08-08 |
| EP2503338A3 (en) | 2013-03-13 |
| DK2201376T3 (da) | 2012-10-15 |
| EP2201376A1 (en) | 2010-06-30 |
| ES2389751T3 (es) | 2012-10-31 |
| JP2011501176A (ja) | 2011-01-06 |
| EP2201376A4 (en) | 2011-03-23 |
| PL2201376T3 (pl) | 2013-01-31 |
| CY1113403T1 (el) | 2016-06-22 |
| DK2503338T3 (en) | 2015-03-09 |
| CY1116089T1 (el) | 2017-02-08 |
| HRP20120743T1 (hr) | 2012-10-31 |
| SI2503338T1 (sl) | 2015-06-30 |
| PT2503338E (pt) | 2015-03-05 |
| US20100209942A1 (en) | 2010-08-19 |
| EP2503338A2 (en) | 2012-09-26 |
| JP4982610B2 (ja) | 2012-07-25 |
| PL2503338T3 (pl) | 2015-06-30 |
| KR20100059902A (ko) | 2010-06-04 |
| JP2012159514A (ja) | 2012-08-23 |
| HRP20150181T1 (hr) | 2015-06-19 |
| EP2503338B1 (en) | 2014-12-24 |
| JP5619810B2 (ja) | 2014-11-05 |
| FI20070795A0 (fi) | 2007-10-24 |
| SI2201376T1 (sl) | 2012-09-28 |
| WO2009053523A1 (en) | 2009-04-30 |
| PT2201376E (pt) | 2012-08-20 |
| ES2532361T3 (es) | 2015-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2201376B1 (en) | A new biomarker for monitoring development of diseases and assessing the efficacy of therapies | |
| Diamant et al. | Toward clinically applicable biomarkers for asthma: an EAACI position paper | |
| Wisniewski et al. | TSG-6 activity as a novel biomarker of progression in knee osteoarthritis | |
| Chaiworapongsa et al. | Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia: Young Investigator Award | |
| Heper et al. | Evaluation of serum C-reactive protein, procalcitonin, tumor necrosis factor alpha, and interleukin-10 levels as diagnostic and prognostic parameters in patients with community-acquired sepsis, severe sepsis, and septic shock | |
| Shipe et al. | Number, activation, and differentiation of circulating fibrocytes correlate with asthma severity | |
| US8975081B2 (en) | Biomarker for monitoring development of diseases and assessing the efficacy of therapies | |
| US20090011444A1 (en) | Detection and diagnosis of inflammatory disorders | |
| JP2025019061A (ja) | 術後有害事象の診断または予後 | |
| Vega et al. | Real-time detection of the chemokine CXCL12 in urine samples by surface plasmon resonance | |
| Koczulla et al. | Alpha-1 antitrypsin is elevated in exhaled breath condensate and serum in exacerbated COPD patients | |
| Engebretsen et al. | Acute hypobaric hypoxia (5486 m) induces greater pulmonary HIF-1 activation in hilltop compared to madison rats | |
| CN116801788A (zh) | 用于评估肝脏疾病的试剂盒、试剂和方法 | |
| Rumora et al. | Assessment of NLRP3 inflammasome activation in patients with chronic obstructive pulmonary disease before and after lung transplantation | |
| CN111094981B (zh) | Pct和pro-adm作为监测抗生素治疗的标记物 | |
| WO2011125858A1 (ja) | バイオマーカー | |
| Gatselis et al. | Calprotectin serum levels on admission and during follow-up predict severity and outcome of patients with COVID-19: A prospective study | |
| Jedynak et al. | Serum concentrations of MCP-1 and RANTES in patients during aortic surgery: the relationship with ischemia-reperfusion | |
| KR20220031084A (ko) | 표피 성장 인자 수용체 저해제에 의해 야기되는 피부 약물 부작용의 위험성 평가 방법, 이의 검출 키트 및 이의 용도 | |
| Sandström et al. | Endotoxin receptor CD14 in PiZ α-1-antitrypsin deficiency individuals | |
| TWI728427B (zh) | 評估表皮生長因子受體抑制劑引發皮膚藥物不良反應風險的方法、其檢測套組及其用途 | |
| Aygun et al. | Evaluation of serum TIE-2 levels in newly diagnosed and untreated multiple myeloma patients | |
| Sumi et al. | Regions of Inflammation in mouse asthma correspond to regions of heme-free soluble guanylyl cyclase and can be tracked by marked expression of heme-oxygenase-1 | |
| Dutta et al. | Diagnosis of infected pancreatic necrosis: A review of the role of blood biomarkers | |
| Ahmed et al. | Characterizing the effect of bariatric surgery on circulating S100A9: Bariatric Surgery |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20130827 |
|
| FZDE | Discontinued |
Effective date: 20201005 |